Axon Enterprise, Inc. (NASDAQ:AXON) Stock Holdings Decreased by Geneva Capital Management LLC

Geneva Capital Management LLC lessened its position in Axon Enterprise, Inc. (NASDAQ:AXON) by 4.8% in the 3rd quarter, according to the company in its most recent filing with the SEC. The institutional investor owned 170,425 shares of the biotechnology company’s stock after selling 8,621 shares during the quarter. Geneva Capital Management LLC owned approximately 0.23% of Axon Enterprise worth $68,102,000 as of its most recent filing with the SEC.

A number of other hedge funds and other institutional investors have also recently added to or reduced their stakes in the company. PFG Investments LLC boosted its position in shares of Axon Enterprise by 0.6% in the third quarter. PFG Investments LLC now owns 3,872 shares of the biotechnology company’s stock worth $1,547,000 after buying an additional 25 shares during the period. Gladstone Institutional Advisory LLC lifted its stake in Axon Enterprise by 1.6% in the 3rd quarter. Gladstone Institutional Advisory LLC now owns 1,641 shares of the biotechnology company’s stock worth $656,000 after acquiring an additional 26 shares in the last quarter. Mather Group LLC. boosted its position in Axon Enterprise by 3.7% during the 3rd quarter. Mather Group LLC. now owns 759 shares of the biotechnology company’s stock worth $303,000 after acquiring an additional 27 shares during the period. CWM LLC grew its stake in Axon Enterprise by 1.3% during the 3rd quarter. CWM LLC now owns 2,856 shares of the biotechnology company’s stock valued at $1,141,000 after acquiring an additional 36 shares in the last quarter. Finally, SPC Financial Inc. increased its holdings in shares of Axon Enterprise by 2.2% in the 3rd quarter. SPC Financial Inc. now owns 1,773 shares of the biotechnology company’s stock valued at $708,000 after purchasing an additional 38 shares during the period. Institutional investors and hedge funds own 79.08% of the company’s stock.

Axon Enterprise Trading Down 3.4 %

Shares of NASDAQ:AXON opened at $595.18 on Wednesday. The company has a market cap of $45.38 billion, a P/E ratio of 153.79, a P/E/G ratio of 15.47 and a beta of 0.94. The stock’s 50-day moving average is $423.98 and its 200-day moving average is $351.79. Axon Enterprise, Inc. has a 52-week low of $216.73 and a 52-week high of $624.84. The company has a debt-to-equity ratio of 0.32, a quick ratio of 2.63 and a current ratio of 2.96.

Insiders Place Their Bets

In related news, Director Caitlin Elizabeth Kalinowski sold 450 shares of the business’s stock in a transaction on Wednesday, August 21st. The shares were sold at an average price of $373.03, for a total transaction of $167,863.50. Following the transaction, the director now owns 7,379 shares of the company’s stock, valued at approximately $2,752,588.37. The trade was a 0.00 % decrease in their ownership of the stock. The sale was disclosed in a legal filing with the SEC, which is available through this hyperlink. In related news, Director Caitlin Elizabeth Kalinowski sold 450 shares of Axon Enterprise stock in a transaction dated Wednesday, August 21st. The stock was sold at an average price of $373.03, for a total transaction of $167,863.50. Following the sale, the director now directly owns 7,379 shares of the company’s stock, valued at $2,752,588.37. This trade represents a 0.00 % decrease in their ownership of the stock. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is available through this hyperlink. Also, Director Julie A. Cullivan sold 900 shares of the company’s stock in a transaction that occurred on Thursday, September 5th. The shares were sold at an average price of $353.53, for a total value of $318,177.00. Following the completion of the transaction, the director now directly owns 3,653 shares of the company’s stock, valued at approximately $1,291,445.09. This trade represents a 0.00 % decrease in their position. The disclosure for this sale can be found here. Insiders have sold a total of 369,172 shares of company stock valued at $136,270,842 in the last three months. Company insiders own 5.70% of the company’s stock.

Analyst Ratings Changes

AXON has been the subject of several research reports. Robert W. Baird raised their price target on shares of Axon Enterprise from $440.00 to $460.00 and gave the stock an “outperform” rating in a report on Monday, November 4th. Needham & Company LLC boosted their price target on shares of Axon Enterprise from $525.00 to $600.00 and gave the company a “buy” rating in a report on Friday, November 8th. Northland Securities lifted their price objective on Axon Enterprise from $365.00 to $550.00 and gave the company an “outperform” rating in a research report on Monday. The Goldman Sachs Group boosted their target price on Axon Enterprise from $385.00 to $441.00 and gave the company a “buy” rating in a research note on Wednesday, October 23rd. Finally, Barclays lifted their price target on Axon Enterprise from $381.00 to $387.00 and gave the company an “overweight” rating in a report on Wednesday, August 7th. Two investment analysts have rated the stock with a hold rating and twelve have given a buy rating to the company. According to data from MarketBeat, the stock currently has an average rating of “Moderate Buy” and a consensus target price of $427.83.

Axon Enterprise Company Profile

Axon Enterprise, Inc develops, manufactures, and sells conducted energy devices (CEDs) under the TASER brand in the United States and internationally. It operates through two segments, Software and Sensors, and TASER. The company also offers hardware and cloud-based software solutions that enable law enforcement to capture, securely store, manage, share, and analyze video and other digital evidence.